Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Fidelity Select Biotechnology Portfolio (FBIOX)

175.92 Down 0.25(0.14%) Apr 17
Get the big picture on all your investments.

Profile as of Mar 30, 2014Get Profile for:
Fidelity Select Biotechnology Portfolio
Fidelity Select Portfolios82 Devonshire StreetBoston MA 02109
Map
Phone: 800-544-8544
Fund Overview 
Category:Health
Fund Family:Fidelity Investments
Net Assets:9.39B
Year-to-Date Return:7.22%
Yield:0.00%
Morningstar Rating:4 stars
Fund Inception Date:Dec 16, 1985
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Rajiv Kaul
Lead Manager since Oct 12, 2005
Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.
Investment Information 
Min Initial Investment:2,500
Min Initial Investment, IRA:200
Min Initial Investment, AIP:2,500
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:200
Min Subsequent Investment, AIP:N/A
FBIOX can be purchased from 85 brokerages.

Fund Summary 
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 5, 2013) : 0.00
Annual Holdings Turnover (Apr 16, 2014) : 42.00%
Average for Category:51.92%
Fees & Expenses 
ExpenseFBIOXCategory Avg
Annual Report Expense Ratio (net):0.79%1.44%
Prospectus Net Expense Ratio:0.81%N/A
Prospectus Gross Expense Ratio:0.81%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.53%
3 Yr Expense Projection*:259657
5 Yr Expense Projection*:4501,030
10 Yr Expense Projection*:1,0022,022
* Per $10,000 invested